

[19] Patents Registry [11] 1247557 B  
The Hong Kong Special Administrative Region  
香港特別行政區  
專利註冊處

[12] **STANDARD PATENT (R) SPECIFICATION**  
**轉錄標準專利說明書**

[21] Application no. 申請編號 [51] Int. Cl.  
18106976.5 A61K 31/00 (2006.01) A61K 31/34 (2006.01)  
[22] Date of filing 提交日期 A61K 31/4164 (2006.01) A61K 31/495 (2006.01)  
28.05.2018 A61K 31/341 (2006.01) A61K 31/426 (2006.01)  
A61P 1/12 (2006.01)

---

[54] PRODUCT AND METHOD FOR TREATING DIARRHEA  
用於治療腹瀉的產品和方法

[30] Priority 優先權 14.03.2013 US 201361782608P	[73] Proprietor 專利所有人 MAREGADE RX LLC 819 Pinehurst Place Jackson, MS 39202 UNITED STATES OF AMERICA
[43] Date of publication of application 申請發表日期 28.09.2018	[72] Inventor 發明人 HOGAN II, Reed, B.
[45] Date of publication of grant of patent 批予專利的發表日期 03.07.2020	[74] Agent and / or address for service 代理人及/或送達地址 HK PAT IP LIMITED Flat C, 10/F., Wing Tat Commercial Building 121-125 Wing Lok Street, Sheung Wan HONG KONG
EP Application no. & date 歐洲專利申請編號及日期 EP 17189072.6 14.03.2014	
EP Publication no. & date 歐洲專利申請發表編號及日期 EP 3269364 17.01.2018	
Date of grant in designated patent office 指定專利當局批予專利日期 29.05.2019	

(19)



Europäisches  
Patentamt  
European  
Patent Office  
Office européen  
des brevets



(11)

EP 3 269 364 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:

29.05.2019 Bulletin 2019/22

(21) Application number: 17189072.6

(51) Int Cl.:

A61K 31/00 (2006.01)

A61K 31/34 (2006.01)

A61K 31/4164 (2006.01)

A61K 31/495 (2006.01)

A61K 31/341 (2006.01)

A61K 31/426 (2006.01)

A61P 1/12 (2006.01)

(22) Date of filing: 14.03.2014

## (54) PRODUCT AND METHOD FOR TREATING DIARRHEA

PRODUKT UND VERFAHREN ZUR BEHANDLUNG VON DIARRHÖE

PRODUIT ET PROCÉDÉ DE TRAITEMENT DE LA DIARRHÉE

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR

(30) Priority: 14.03.2013 US 201361782608 P

(43) Date of publication of application:

17.01.2018 Bulletin 2018/03

(60) Divisional application:

19169633.5

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:

14722445.5 / 2 968 205

(73) Proprietor: Maregade RX, LLC  
Jackson, MS 39202 (US)

(72) Inventor: HOGAN II, Reed B.  
Jackson, MS 39202 (US)

(74) Representative: Hobson, David James et al  
Mathys & Squire LLP  
The Shard  
32 London Bridge Street  
London SE1 9SG (GB)

(56) References cited:  
WO-A2-2008/128115 US-A1- 2009 042 972

- Mohammad Reza Ghadir M.D ET AL: "Doxepin is More Effective than Nortriptyline and Placebo for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Triple-Blind Placebo-Controlled Trial", Tehran University Medical Journal, 1 June 2011 (2011-06-01), pages 352-358, XP055423025, Retrieved from the Internet:  
URL:<http://tumj.tums.ac.ir/article-1-221-e.pdf> [retrieved on 2017-11-08]
- DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2011 (2011-01), SPIEGEL DAVID R ET AL: "Treatment of Irritable Bowel Syndrome With Comorbid Anxiety Symptoms With Mirtazapine", XP002725424, Database accession no. PREV201100096461
- Shriram Jakate ET AL: "Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea", Archives of pathology & laboratory medicine, 1 March 2006 (2006-03-01), page 362, XP055121580, United States Retrieved from the Internet:  
URL:<http://www.ncbi.nlm.nih.gov/pubmed/16519565>
- FONDACARO J D ET AL: "Cecectomized rat - A model of experimental secretory diarrhea in conscious animals", JOURNAL OF PHARMACOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 24, no. 1, 1 August 1990 (1990-08-01) , pages 59-71, XP023772610, ISSN: 0160-5402, DOI: 10.1016/0160-5402(90)90050-U [retrieved on 1990-08-01]

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- E. M. BERRY ET AL: "Carcinoid myopathy and treatment with cyproheptadine (Periactin)", GUT, vol. 15, no. 1, 1 January 1974 (1974-01-01), pages 34-38, XP055121680, ISSN: 0017-5749, DOI: 10.1136/gut.15.1.34
- Anonymous: "Nortriptyline - Wikipedia", , 1 January 2017 (2017-01-01), XP055423272, Retrieved from the Internet:  
URL:<https://en.wikipedia.org/wiki/Nortriptyline> [retrieved on 2017-11-09]
- Anonymous: "Drugs & Biologics Search Results for Doxepin hydrochloride", , 1 January 2017 (2017-01-01), XP055423276, Retrieved from the Internet:  
URL:[https://integrity.thomson-pharma.com/integrity/xmlxsl/pk\\_qcksrch.show\\_records?sessionID=1&history=&query=doxepin&abbreviation=PRO&language=en](https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_qcksrch.show_records?sessionID=1&history=&query=doxepin&abbreviation=PRO&language=en) [retrieved on 2017-11-09]

**Description****BACKGROUND**

5 [0001] Diarrhea is a common condition characterized by increased frequency or fluidity of bowel movements. Diarrhea may cause dehydration and electrolyte abnormalities that may require hospitalization to replace lost fluids and electrolytes until the symptoms subside. Persistent, uncontrolled diarrhea can cause such severe malnutrition, electrolyte imbalances and dehydration that it may ultimately result in death. Acute diarrhea is usually treated with fluid and electrolyte replacement, dietary modifications and antidiarrheal or antimicrobial agents. Acute diarrhea complications may cause severe 10 illness, especially in high-risk groups, for example patients with underlying immunosuppression or advanced age. Anti-diarrheal treatment is also required in patients with chronic diarrhea. Empiric therapies routinely used for chronic diarrhea include: stool-modifying agents (such as psyllium and fiber), anticholinergic agents, opiates, antibiotics, and probiotics.

15 [0002] Chronic diarrhea may be a symptom of a chronic disease, for example irritable bowel syndrome (IBS). It has been estimated that the prevalence of chronic diarrhea in the United States is approximately 5%. IBS alone is estimated to affect 15-20% of the U.S. population, and accounts for at least 30% of all gastroenterology health care costs. In many cases, the cause of the chronic diarrhea is not found, the diagnosis remains uncertain, and empiric treatments are unsuccessful. Thus, there is an ongoing need for antidiarrheal agents that effectively stop or greatly reduce bowel movements and fluid loss in patients undergoing treatment, to remove the cause of diarrhea, or in patients in which the cause of diarrhea is not found.

20 [0003] H1 and H2 receptor antagonists are two classes of antihistamines. H1 receptor antagonists are used in the symptomatic treatment of multiple conditions, including allergic rhinoconjunctivitis, relief of pruritus in patients with urticaria, and in patients with chronic asthma. Newer H1 receptor antagonists, such as cetirizine, are referred to as second-generation H1 receptor antagonists, and are more selective for peripheral H1 receptors than first-generation H1 receptor antagonist, which antagonize both the central and peripheral nervous system H1 receptors as well as cholinergic receptors. The selectivity significantly reduces the occurrence of adverse drug reactions, such as sedation, while still 25 providing effective relief of allergic conditions.

[0004] H2 receptor antagonists are used primarily to treat symptoms of acid reflux, or gastroesophageal reflux disease. H2 receptor antagonists reduce the production of stomach acid. Often diarrhea is listed as a major side effect of H2 receptor antagonists.

30 [0005] Diphenhydramine, a first-generation H1 receptor antagonist, together with either cimetidine or ranitidine, H2 receptor antagonists, have been studied for the treatment of acute allergic reactions. In a first study (Runge et al. "Histamine antagonists in the treatment of acute allergic reactions" Ann Emerg Med (Mar. 1992) 21:237-242), patients were treated by a single intravenous administration of a solution of 300 mg cimetidine and placebo, 50 mg diphenhydramine and placebo, or diphenhydramine plus cimetidine; the treatment was found effective for acute urticaria. In a 35 second study (Lin et al. "Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists" Ann Emerg Med (Nov. 2000) 36:462-468), patients were treated by a single parenteral administration of a solution of either 50 mg diphenhydramine and saline or 50 mg diphenhydramine and 50 mg ranitidine; the treatment was found effective for acute allergic syndromes.

40 [0006] Ghadir et al (2011), Tehran University Medical Journal, 69, 6, 352-358 describes doxepin as purportedly being more effective than nortriptyline and placebo for the treatment of diarrhea-predominant irritable bowel syndrome.

[0007] WO 2008/128115 A2 describes low dose doxepin formulations and methods of making and using the same.

[0008] US 2009/042972 A1 describes methods of using low-dose doxepin for the improvement of sleep.

[0009] Spiegel et al (2011), Clin Neuropharmacol, 34(1), 36-38 describes treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine.

45 [0010] Jakate et al (2006), Arch Pathol Lab Med, 130, 362-367 describes increased mucosal mast cells in chronic intractable diarrhea.

[0011] Fondacaro et al (1990), Journal of Pharmacological Methods, 24, 59-71 describes a model of experimental secretory diarrhea in conscious animals.

[0012] Berry et al (1974), Gut, 15, 34-38 describes carcinoid myopathy and treatment with cyproheptadine (Periactin).

50

**SUMMARY**

55 [0013] In a first aspect, the present invention is an H1 receptor antagonist and an H2 receptor antagonist for use in treating a patient having chronic idiopathic diarrhea, wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof. Preferably, the H1 receptor antagonist comprises cetirizine and the H2 receptor antagonist comprises famotidine.

[0014] In a second aspect, the present invention is an H1 receptor antagonist and an H2 receptor antagonist for use in treating a patient having IBS-diarrhea predominate (IBS-D), wherein the patient does not have mastocytic enterocolitis,

wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof. Preferably, the H2 receptor antagonist is not ranitidine.

**[0015]** In a third aspect, the present invention is a pharmaceutical composition for use in treating a patient having chronic idiopathic diarrhea, said pharmaceutical composition comprising:

5 a. an H1 receptor antagonist, wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof; and

10 b. an H2 receptor antagonist.

Preferably, the H2 receptor antagonist is not ranitidine, and the pharmaceutical composition is an oral dosage form.

**[0016]** In a fourth aspect, the present invention is a pharmaceutical composition for use in treating a patient having IBS-D, wherein the patient does not have mastocytic enterocolitis, said pharmaceutical composition comprising:

15 a. an H1 receptor antagonist, wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof; and

20 b. an H2 receptor antagonist.

## DEFINITIONS

**[0017]** The term "diarrhea" means increased fluidity or frequency of stools.

**[0018]** The term "acute diarrhea" is ongoing diarrhea which has occurred for at most 4 weeks.

**[0019]** The term "chronic diarrhea" is ongoing diarrhea for more than 4 weeks.

**[0020]** The term "unit dosage form" means a single pre-measured dose, and includes tablets, pills, capsules, packets, suspensions, transdermal patches, and rectal suppositories.

## BRIEF DESCRIPTION OF THE DRAWINGS

30 **[0021]** FIG. 1 illustrates participants and responses by treatment group of an IBS-D study.

## DETAILED DESCRIPTION

**[0022]** The present invention makes use of the discovery that administering an H1 receptor antagonist and an H2 receptor antagonist to a patient, results in a significant reduction or cessation of diarrhea. Applicant discovered that the combination of an H1 receptor antagonist and an H2 receptor antagonist administered to patients with diarrhea, resulted in 85-90% positive responders (see Example 7 and Table 1). A positive responder is identified as having a 50% or more reduction in the number of stools per day or a change in stool formation from liquid to solid. No adverse reactions or events were reported. A control group was treated with fiber (Metamucyl®) and an anticholinergic (Bentyl®); positive responders in the control group were less than 25%.

**[0023]** In a prior study (Jakate, et al., "Mastocytic Enterocolitis: Increased mucosal mast cells in chronic intractable diarrhea" Arch Pathol Lab Med (2006) 130:362-367), 33 patients who had increased mast cells (greater than 20 mast cells per high-power field) and were therefore identified by the authors as having "mastocytic enterocolitis," were administered a 2-week regimen of 10 mg per day of cetirizine hydrochloride (an H1 receptor antagonist) and 300 mg twice a day of ranitidine hydrochloride (an H2 receptor antagonist). In 8 of the 33 patients, a third drug, 200 mg/10 mL of cromolyn sodium (a mast cell mediator release inhibitor) was given 4 times daily for 4 to 6 weeks. The patients were followed for resolution, improvement, or persistence of symptoms. The patients who did not have mastocytic enterocolitis were not given these drugs. At follow-up, 22 (67%) of the 33 study patients showed cessation of diarrhea or significant reduction in diarrhea (defined as greater than or equal to 50% reduction in stool frequency or as greater than or equal to 50% improvement in stool consistency). However, because no control was used in the study, and because of the use of a third drug in some of the patients, it is not possible to determine how effective the treatment was for the selected patients. The placebo effect could account for up to about 11 of the patients with a positive outcome and the third drug could account for up to 8 of the patients with a positive outcome. The time frame of the follow-up was not provided. Furthermore, no statistical analysis or further studies were described.

**[0024]** Treating diarrhea by administering an H1 receptor antagonist and an H2 receptor antagonist in combination is described herein. Unit dosage forms, multi-dosage forms, and kits, including an H1 receptor antagonist and an H2 receptor antagonist are described herein. Preferably, the H1 receptor antagonist includes cetirizine and the H2 receptor antagonist includes famotidine.

[0025] Diarrhea may be acute or chronic. Diarrhea may also be further classified:

[0026] Secretory diarrhea: diarrhea which occurs when the intestine does not complete absorption of water from luminal contents and electrolyte absorption is impaired, often caused by bacterial toxins, surgically reduced absorptive area of the intestines, microscopic colitis and luminal secretagogues such as laxatives and bile acids.

5 [0027] Osmotic diarrhea: diarrhea which results from intestinal malabsorption of ingested non-electrolytes.

[0028] Inflammatory diarrhea: diarrhea which may be characterized by blood and pus in the stool and possibly an elevated fecal calprotectin level, and inflammation exhibited on intestinal biopsy, caused by, for example, Crohn's disease and ulcerative colitis.

10 [0029] IBS-diarrhea predominate ("IBS-D"): chronic diarrhea associated with abdominal pain. In order to have IBS, a patient must have experienced onset of symptoms 6 months prior to diagnosis and must have recurrent abdominal pain or discomfort at least three days per month in the last three months associated with two or more of the following: improvement with defecation; onset associated with a change in frequency of stool; onset associated with a change in form of stool. Once IBS is diagnosed, it can be further classified based on the patients predominant symptom: diarrhea (IBS-D), or constipation (IBS-C), or mixed (IBS-M).

15 [0030] Functional diarrhea: chronic diarrhea in a patient who does not meet the criteria for IBS, and for which no other cause can be determined. This type of diarrhea may also be referred to as chronic idiopathic diarrhea.

[0031] Malabsorptive diarrhea: diarrhea caused by an enteropathy such as celiac disease (celiac sprue) and giardiasis, which is characterized by excess gas, steatorrhea, and/or weight loss.

20 [0032] Drug induced diarrhea: diarrhea caused by a drug or treatment for an unrelated disease state, such as chemotherapy, radiation therapy, antibiotic therapy, anti-ulcer therapy, and herbal therapies.

[0033] Food intolerance diarrhea: diarrhea which is associated with dietary intake, such as lactose, sugar substitutes or other food substances.

25 [0034] Particularly common is IBS associated diarrhea, a chronic diarrhea, also referred to IBS-diarrhea predominate or simply "IBS-D". Some researchers claimed to have identified a subset of IBS-D, mastocytic enterocolitis, which they defined as a patient having greater than 20 mast cells per high-power field, based on an average of 10 high-power fields, for at least 2 separate biopsy pieces from random parts of the intestinal mucosa, using an original magnification of X400, an objective having magnification of X40 and an eyepiece having magnification of X10 (Jakate, et al., "Mastocytic Enterocolitis: Increased mucosal mast cells in chronic intractable diarrhea" Arch Pathol Lab Med (2006) 130:362-367). In an aspect of the present invention, the patient does not have mastocytic enterocolitis.

30 [0035] H1 receptor antagonists block H1 histamine receptors; first-generation H1 receptor antagonists block histamine receptors in the central and peripheral nervous systems, as well as cholinergic receptors, while second-generation H1 receptor antagonists are selective for H1 histamine receptors in the peripheral nervous system. First-generation H1 receptor antagonists include brompheniramine, chlorpheniramine, dexbrompheniramine, dexchlorpheniramine, pheniramine, triprolidine, carboxamine, clemastine, diphenhydramine, pyrilamine, promethazine, hydroxyzine, azatadine, cyproheptadine, and phenindamine. Second-generation H1 receptor antagonists include ketotifen, rupatadine, mizolastine, acrivastine, ebastine, bilastine, bepotastine, terfenadine, quifenadine, azelastidine, cetirizine, levocetirizine, desloratadine, fexofenadine and loratadine. The H1 receptor antagonist comprises cetirizine or levocetirizine or mixtures thereof, with cetirizine being particularly preferred.

35 [0036] The H1 receptor antagonists may be used in an amount of from 0.1 to 10 times the amount typically used for the treatment of allergies, for example in an amount of 0.1 to 600 mg per dose, 0.5 to 500 mg per dose, 1.0 to 50 or 60 mg per dose, including 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40 and 45 mg per dose. Preferably, the H1 receptor antagonist is administered 1, 2, 3 or 4 times per day. The H1 receptor antagonist may be administered as an injectable formulation, for example intravenously, intraparenterally or intramuscularly; transdermally, via a transdermal patch; or, preferably, orally, as a powder, table or capsule, an oral solution or suspension, or sublingual or buccal tablets. Alternative forms of administration include rectal suppositories, inhaled, epidural, subcutaneous, nasal spray, transmucosal, and intradermal formulations.

40 [0037] H2 receptor antagonists block H2 histamine receptors. H2 receptor antagonists include cimetidine, ranitidine, famotidine, and nizatidine, with famotidine being preferred. Mixtures and combinations of H2 receptor antagonists may also be used.

45 [0038] The H2 receptor antagonists may be used in an amount of from 0.1 to 10 time the amount typically used for treatment dyspepsia, for example 1.0 to 8000 mg per dose, 2.0 to 1000 mg per dose, 5.0 to 800 mg per dose, including 6.0, 7.0, 8.0, 9.0, 10, 15, 20, 21, 22, 22.5, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 120, 140, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, and 700 mg per dose. Preferably, the H2 receptor antagonist is administered 1, 2, 3 or 4 times per day. The H2 receptor antagonist may be administered as an injectable formulation, for example intravenously, intraparenterally or intramuscularly; transdermally, via a transdermal patch; or, preferably, orally, as a powder, table or capsule, an oral solution or suspension, or sublingual or buccal tablets. Alternative forms of administration include rectal suppositories, inhaled, epidural, subcutaneous, nasal spray, transmucosal, and intradermal formulations.

**[0039]** Patients often respond to treatment within 48 to 72 hours. However, treatment should be carried out for an amount of time to resolve any underlying cause in the case of acute diarrhea, for example 3 to 14 days, or 5 to 10 days. In the case of chronic diarrhea, a 30 day trial is reasonable, and if the underlying cause of the diarrhea cannot be resolved, for example in the case of IBS-D, then treatment should be continued indefinitely.

5 **[0040]** Preferably, the H1 and H2 receptor antagonists are administered simultaneously, as a unit dosage form containing both receptor antagonists. Examples of unit dosage forms include oral compositions, such as tablets (for example, sublingual or buccal tablets), capsules (for example, hard gelatin and soft gelatin capsules), transmucosal and sublingual patches and films, pre-measured powder packets and saches, flavored and/or sweetened aqueous solutions or suspensions. Because diarrhea is often associated with dehydration, flavored and/or sweetened aqueous solutions or 10 suspension may be oral rehydration solutions, or solutions which also contain sodium and glucose or a glucose-containing saccharide, in amounts of 250 ml, 500 ml or 1 liter of fluid. Furthermore, a pre-measured powder packet, containing the receptor antagonists, together with sodium (for example, as sodium chloride) and glucose or a glucose-containing saccharide, and optionally other excipients, flavorings and/or sweeteners, may be provided, which may be readily mixed with water prior to consumption. Preferably, the oral unit dosage form is present as a once-per-day dosage.

15 **[0041]** Examples of oral dosage forms include a tablet containing famotidine, in an amount of 5, 10, 15, 20, 22.5, 25, 30, 35 or 40 mg, as a core, and a coating of cetirizine, in an amount of 2.5, 5, 8.5, 10, 15, or 20 mg. Another example includes a capsule containing granules of famotidine and cetirizine in water-soluble matrix. In another example, both the famotidine and the cetirizine are present as a mixture in a matrix, either as a table or within a capsule. In these examples, other H1 and/or H2 receptor antagonists may be used in place of, or in addition to, famotidine and/or cetirizine.

20 **[0042]** Other unit dosage forms are described herein, containing both H1 and H2 receptor antagonist. For example, injectable formulation containing a sterile solution or suspension, including formulation for administration intravenously, intraparenterally or intramuscularly, may be provided. A unit dosage form for administration transdermally, via a transdermal patch, may be provided. Other unit dosage forms include rectal suppositories, inhaled, epidural, subcutaneous, nasal spray, and intradermal formulations. Excipients and adjuvants maybe also be included in any of the unit dosage 25 forms, both oral and non-oral.

25 **[0043]** Multi-dosage forms, such as kits, containing 2 to 30, 3 to 25, or 5 to 14 unit dosage forms, for example 6, 7, 8, 9, 10, 11, 12, 13, 15, 20, 40, 50 or 60 unit dosage forms, are described herein. Multi-dosage forms containing sufficient unit dosage forms for administration over a period of 2 to 30, 3 to 25, or 7 to 14 days, for example 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 20 or 30 days, are described herein. Kits are described herein, which include oral rehydration solutions, or 30 powders which may be hydrated to form oral rehydration solutions, or kits containing sodium and glucose or a glucose-containing saccharide, as well as other excipients, flavorings and/or sweeteners, together with unit dosage forms.

## EXAMPLES

35 Example 1: treatment of secretory diarrhea (not part of the invention)

**[0044]** Patient #1, age 65, was hospitalized for more than one week for weight and fluid loss related to chronic diarrhea. The patient had from 20 to 40 stools per day and severe life threatening diarrhea. The patient was treated with 20 mg famotidine and 10 mg cetirizine, once per day. Symptoms subsided within 48 hours with a 95% decrease in the number 40 of stools and the patient was discharged. The patient responded to treatment and now has 1 stool per day, occasionally two, but no diarrhea.

Example 2: treatment of IBS diarrhea

45 **[0045]** Seven patients, age 26 to 80, were treated for mild to severe diarrhea, ranging from 3 to 18 stools per day.

Patient #1, age 80, with mild to severe cramping and 4 to 5 stools a day. The patient was treated with 300 mg ranitidine and 10 mg cetirizine, once per day. The patient reported a 60% reduction in the number of stools.

50 Patient #2, age 62, had severe weight loss, greater than 30 pounds, related to the diarrhea, 10 to 20 stools per day, and was opiate and steroid dependant. The patient was treated with 20 mg famotidine and 10 mg cetirizine, once per day. Treatment was successful with an 85 to 90% reduction in the number of stools. The patient now has 1 to 2 stools per day for over 8 months on treatment.

55 Patient #3, age 65, prior to treatment was homebound, had 4 to 5 stools per day, each episode lasting an hour or two. The patient was treated with 300 mg ranitidine and 10 mg cetirizine, once per day. Treatment was successful, with the patient reporting a 90% reduction in the number of stools.

Patient #4, age 67, with moderate diarrhea and cramping, had 4 to 5 stools per day. The patient was treated with 20 mg famotidine and 10 mg cetirizine, once per day. Treatment was successful, with a 75% reduction in the number of stools, no cramping and no side effects.

5 Patient #5, age 26, had moderate to severe diarrhea with 7 to 8 stools per day. The patient was treated with 20 mg famotidine and 10 mg cetirizine, once per day. Treatment was successful, with a decrease in the number of stools by 50%, down to 3 to 4 per day, with no side effects.

10 Patient #6, age 74, with severe diarrhea, had 8 stools per day and was homebound. The patient was treated with 300 mg ranitidine and 10 mg cetirizine, once per day. Treatment was successful, with a decrease in the number of stools by 75%, down to 2 stools per day and no side effects. Patient is presently only on cetirizine.

15 Patient #7, age 51, with colon resection, had severe diarrhea with 15 to 20 stools per day. The patient was treated with 300 mg ranitidine and 10 mg cetirizine, once per day. Treatment was successful, with a decrease in the number of stools by 94%, to 1 to 2 stools per day and better consistency, with no side effects.

Example 3: chronic idiopathic diarrhea

20 [0046] A patient, age 81, with a complaint of moderate diarrhea and no additional diagnoses, had 4 to 6 stools per day, causing interference with activity level and lifestyle. The patient was treated with 20 mg famotidine and 10 mg cetirizine, once per day. Treatment was successful, with a decrease in the number of stools by 70%, to 1 to 2, mostly 1, per day and a repeat colonoscopy was cancelled because symptoms had resolved.

25 Example 4: chemotherapy induced diarrhea (not part of the invention)

30 [0047] Patient, age 64, with colon cancer and moderate to severe diarrhea, in a deconditioned state from chemotherapy agents, had 5 to 10 stools per day. The patient was treated with 20 mg famotidine and 10 mg cetirizine, once per day. Treatment was successful, with a decrease in the number of stools by 80%, to 1 to 2 per day and normal consistency, with no side effects.

35 Example 5: inflammatory diarrhea - ulcerative colitis/Crohn's disease (not part of the invention)

[0048] Three patients, age 35-64, were treated for severe diarrhea related to ulcerative colitis or Crohn's disease.

40 Patient #1, age 64, with Crohn's disease, had 12 to 15 stools per day and severe diarrhea. The patient was treated with 20 mg famotidine and 10 mg cetirizine, once per day. Treatment was not successful, with a decrease in the number of stools only by 5%. There were no side effects.

45 Patient #2, age 37, with Crohn's disease and colitis, had severe diarrhea with 4 to 5 stools per day. The patient was treated with 300 mg ranitidine and 10 mg cetirizine, once per day. Treatment was successful, with a decrease in the number of stools by 75%, to one stool per day and normal consistency. There were no side effects.

50 Patient #3, age 35, with ulcerative colitis, had severe diarrhea with 4 to 6 stools per day. The patient was treated with 20 mg famotidine and 10 mg cetirizine, once per day. Treatment was successful, with a decrease in the number of stools by 50%. There were no side effects.

Example 6: celiac disease (not part of the invention)

55 [0049]

Patient #1, age 57, with celiac disease had mild to moderate diarrhea, with 2 to 4 stools per day. The patient had no improvement from treatment with 20 mg famotidine and 10 mg cetirizine, once per day. There were no side effects.

Patient #2, age 26, with celiac disease. The patient had little improvement from treatment.

55 Example 7: IBS-D Treatment Study

[0050] The study population age was 18 to 80, with the patients having chronic unexplained diarrhea from an outpatient

population of a clinic and outpatients from a medical center, who gave consent for treatment. Patients were excluded who had a history of systemic or cutaneous mastocytosis, definable etiology of diarrhea (other than IBS-D or chronic idiopathic diarrhea) such as celiac disease, inflammatory bowel disease, or lactose intolerance, or who were pregnant. The study was initiated after IRB approval.

5 [0051] Upon referral to the study coordinator, and after informed consent was obtained, patients were assigned to one of the two study arms. Patients underwent colonoscopy with biopsies that were then evaluated by a pathologist who was blind to the study arm. The study coordinator reviewed pathology results and documents accordingly. The patient was provided the treatment method that was randomly assigned and given a diary to document symptoms. Follow up phone conversations and a return visit was scheduled. At the completion of the four week medication treatment period, 10 a telephone call or visit was carried out. At eight weeks, the diary was returned and the coordinator documented the data recorded by the subjects. There was a process for adverse event reporting and to date, no adverse reactions or events have been reported.

15 [0052] One study arm received famotidine (20 mg per day) and cetirizine (10 mg per day), once per day. The second study arm received fiber (Metamucil®) and an anticholinergic (Bentyl®) once per day. Table 1 shows the results of the study. Tables 2 and 3 show the statistical analysis of the study results.

Table 1: Study results

Treatment Group	Number of Participants	Positive Responders	Non-Responders	Percent Responding
famotidine and cetirizine	26	25	1	96%
dicylcomine and psyllium	8	2	6	25%

Positive responders = Appreciable decrease in # of stools per day  
Non-responders = No appreciable decrease in # of stools per day

Table 2: Group statistics

Treatment Group	N	Mean	Std. Deviation	Std. Error Mean
dicylcomine and psyllium	8	0.13	0.354	0.125
famotidine and cetirizine	26	1.00	0.000	0.000

Table 3: Independent samples test

Status	Independent Samples Test								
	Levene's Test for Equality of Variances		t-test for Equality of Means						
	F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	Lower
Equal variances assumed	19.033	0.000	-13.088	32	0.000	-8.75	0.67	-1.011	-.739
Equal variances not assumed	19.033	0.000	-7.000	7.000	0.000	-8.75	0.125	-1.171	-.579

[0053] Figure 1 illustrates participants and responses by treatment group. The bars on the left represent the patients

who received famotidine and cetirizine, while the bars on the right represent the patients who received fiber and anti-cholinergic. As indicated in the table and the figure, 90% of the patients receiving famotidine and cetirizine responded to the treatment, while only 10% of those receiving fiber and anticholinergic responded to the treatment.

**[0054]** Tables 4 and 5 show the percent decrease in number of stools per day, for the famotidine and cetirizine study arm, and the dicylcomine and psyllium study arm, respectively.

Table 4: Percent decrease in number of stools per day, for the famotidine and cetirizine study arm

Number of Subjects	Percent Stool Decrease
1	0%
1	10-25%
2	28-45%
11	50-65%
11	66-85%
0	>86%

Table 5: Percent decrease in number of stools per day, for the dicylcomine and psyllium study arm

Number of Subjects	Percent Stool Decrease
6	0%
0	10-25%
1	28-45%
1	50-65%
0	66-85%
0	>86%

#### Example 8: Chronic Diarrhea Treatment Study

**[0055]** The study population age was 21 to 70, with patients diagnosed with chronic diarrhea, who gave consent for treatment. Patients were excluded if there was a sensitivity or allergy to H1 receptor antagonists or H2 receptor antagonists, renal impairment or a history of renal failure, a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis), a known active infection of the colon (such as *Clostridium difficile*, giardia, or *Salmonella*), biopsy proven microscopic colitis (collagenous or lymphocytic colitis), or an inability to discontinue other anti-diarrheal agents during the study. Patients were also excluded if they were pregnant or lactating women, or if the patient was taking atazanavir, itraconazole, or ketoconazole. The study was initiated after IRB approval.

**[0056]** The study was a 4-week randomized, double-blind, controlled trial, with crossover. After informed consent was obtained, patients were randomly assigned to one of the two groups (active or placebo), with neither the patients nor the physicians knowing to which group each patient was assigned. Each patient was provided the treatment method that was randomly assigned and given a diary to document symptoms. After 7 days of treatment, subjects participated in a telephone interview with a blinded member of the research team. Crossover was allowed after one week of treatment for non-responders. At the end of the 28 day study, the patients completed a detailed questionnaire. Stool quality was evaluated using the 7 point Bristol Stool Scale.

**[0057]** The "active" group received famotidine (24 mg) and cetirizine (9 mg), once per day, with both drugs combined in the form of a single capsule. The "placebo" group received a capsule once per day, which contained no active ingredients.

**[0058]** The results of the study are shown in Table 6. The table shows the results of 27 patients, 12 in the placebo group and 15 in the active group. The average value for percent change in stools per day (SPD) was 25.08 for the placebo group, while the average value for percent change in SPD was 46.00 for the active group. Only 3 of the active group patients agreed to crossover, while 9 of the placebo group patients agreed to crossover. The data demonstrate a clinical significance between the placebo group and the active group, and demonstrate a significant improvement in the quality of life of the patients in the active group.

Table 6: Results of Chronic Diarrhea Treatment Study

Group	Number of Patients	Mean Δ% SPD
Placebo	12	25.08
Active	15	46.00

## REFERENCES

[0059]

[85] Schiller LR, "Secretory Diarrhea" Current Gastroenterology Reports (1999) 1:389-397.

[86] Schiller, LR, Hogan RB, Morawski, SG, Santa Ana, CA, Bern MJ, Nogaard, RP, Bo-Linn, GW, Fordtran JS, "Studies of the Prevalence and Significance of Radiolabeled Rice Acid Malabsorption in a Group of Patients with Idiopathic Chronic Diarrhea" Gastroenterology (1997) 92:151-160.

[87] Fordtran JS, Santa Ana CA, Morawski SG, et al. "Pathophysiology of chronic diarrhea: insights derived from intestinal perfusion studies in 31 patients" Gastroenterol Clin North Am (1986) 15:477-490.

[88] Lunardi C, Bambara LM, Biasi D, et al. "Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance" Clin Exp Allergy (1991) 21: 569-572.

[89] Fine KD, Schiller UR, "AGA technical review on the evaluation and management of chronic diarrhea" Gastroenterology (1999) 116:1464-1486.

[90] O'Sullivan et al. "Increased mast cells in the irritable bowel syndrome" Neurogastroenterol. Mot. (2000) 12:449-457.

[91] Spiller RC, Jenkins D, Thornley JP, Hebdon JM, Wright T, Skinner M, Neal KR, "Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute *Campylobacter* enteritis and in post-dysenteric irritable bowel syndrome" Gut (Dec. 2000) 47(6):804-11.

[92] Theoharides TC Cochrane DE, "Critical role of Mast Cells in inflammatory diseases and the effect of acute stress" J Neuroimmunol (2004) 146:1-12.

[93] Barbars G, De Giorgio et al. "New pathophysiological mechanisms in irritable bowel syndrome" Aliment Pharmacol Ther (2004) 20(suppl. 2):1-9.

[94] Dunlop SP, Hebdon et al. "Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes" Am J Gastroenterol (2006) 101(6):1288-1294.

[95] Barbara G, Stanghellini V et al. "Functional gastrointestinal disorders and mast cells: implications for therapy" Neurogastroenterol Motil (2006) 18:6-17.

[96] Halvorson HA et al. "Postinfectious irritable bowel syndrome-a meta-analysis" Am J Gastroenterol (2006) 101:1894-1899.

[97] Posserud I et al. "Small intestinal bacterial overgrowth in patients with irritable bowel syndrome" Gut (2007) 56:802-808.

[98] Lewis, J, Candelora, J, Hogan, II, RB, Briggs, F, Abraham, S, "Crystal-Storing Histiocytosis Due to Massive Accumulation of Charcot-Leyden Crystals: A Unique Association Producing Colonic Polyposis in a 78-year-old Woman With Eosinophilic Colitis" Am J Surg Pathol. (Mar. 2007) 321(3):481-485.

[99] Jakate S, et al. "Mastocytic enterocolitis increased mucosal mast cells in chronic intractable diarrhea" Arch Pathol Lab Med, (2006) 130:362-367.

[100] Kirsch RH, Riddell R, "Histopathological alterations in irritable bowel syndrome" *Modem Pathology* (2006) 19:1638-1645.

5 [101] Ramos L, Vicario M, Santos J, "Stress-mast cell axis and regulation of gut mucosal inflammation: from intestinal health to an irritable bowel" *Med Clin (Barc)* (Jun. 2007) 129(2):61-69.

[102] Piche T, Saint-Paul MC et al. "Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome" *Gut* (2008) 57:468-473.

10 [103] Visser J, Rozing et al. "Tight Junctions, intestinal permeability and autoimmunity celiac disease and type 1 diabetes paradigms" *Ann N Y Acad Sci* (2009) 1165:195-205.

15 [104] Walker MM, Talley NJ, et al. "Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia" *Aliment Pharmacol Ther* (2009) 29:765-773.

[105] Thabane M, Marshall JK, "Post-infectious irritable bowel syndrome" *World J Gastroenterol.* (2009) 15(29):3591-3596.

20 [106] Walker MM, Salehian SS et al. "Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia" *Aliment Pharmacol Ther* (2010) 31:1229-1236.

25 [107] Klooster TK, Braak B, Koopman KE et al. "The mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome" *Gut* (2010) 59:1213-21.

[108] Martinez C, et al. "The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations" *Am J Gastroenterol* (2012) 107:736-746.

30 [109] Theoharides TC, Shahrzad A, Chen J, Huizinga J, "Irritable Bowel Syndrome and the Elusive Mast Cell" *Am J Gastroenterol* (2012) 107:727-729.

[110] Smith MJ, "IBS remains a mysterious disorder with few effective Remedies" *Gastroenterology and Endoscopy News* (April 2012) Vol. 63:4.

35 [111] Pyleris E, Giamparellos-Bourboulis EJ, et al. "The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome" *Dig Dis Sci.* (May 2012) 57(5):1321-9.

40 [112] Vivinus-Nebot M, Dainese R, et al. "Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells" *ACG* (2012) 107:74-81

[113] Akhavein A, Patel NR, et al. "Allergic Mastocytic Gastroenteritis and colitis: and unexplained etiology in chronic abdominal pain and gastrointestinal dysmotility" *Gastroenter Research and Practice* (2012) 2012:950582.

45 [114] Martinez C, Lobo B, et al. "Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier" *Gut* (2012) [Epub ahead of print: 25 May 2012].

[115] Braak B, Klooster TK et al. "Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?" *Am J Gastroenterol* (2012) 107:715-726.

50 [116] Theoharides TC, Asadi S, Chen J, Huizinga JD, "Irritable bowel syndrome and the elusive mast cells" *Am J Gastroenterol* (2012) 107(5):727-729.

[117] Farhadi A, Fields JZ, Keshavarzian A, "Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation" *World J Gastroenterol* (2007) 13(22):3027-3030.

[118] Juckett G, Trivedi R, "Evaluation of chronic diarrhea" *American Family Physician* [serial online]. November

15, 2011;84(10):1119-1126.

[119] Diarrhea [electronic resource]/ National Digestive Diseases Information Clearinghouse. (2011). Bethesda, MD: U.S. Dept. of Health and Human Services, National Institutes of Diabetes and Digestive and Kidney Diseases.

5

[120] Forbes D, O'Loughlin E, Scott R, Gall D, "Laxative abuse and secretory diarrhoea" Arch Dis Child (1985) 60(1):58-60.

10

[121] DuPont, H.L. et al., "Diarrhea", National Digestive Diseases Information Clearinghouse, January 2012.

15

[122] Lever, D.D., et al., "Acute Diarrhea", Center for Continuing Education publications: Disease Management Project, Cleveland Clinic, August 1, 2010.

20

[123] H2 blockers, MedlinePlus®, U.S. National Library of Medicine, NIH, updated: August 11, 2011.

15

[124] Runge et al. "Histamine antagonists in the treatment of acute allergic reactions" Ann Emerg Med (Mar. 1992) 21:237-242.

20

[125] Lin et al. "Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists" Ann Emerg Med (Nov. 2000) 36:462-468.

25

[126] He, Shuang; Li, Feng; Zhou, Dan; Du, Junrong; Huang, Yuan, Drug development and industrial pharmacy, (Oct. 2012) 38(10)1280 -1289.

30

[127] Akin C, Valent P, Metcalfe DD "Mast cell activation syndrome: Proposed diagnostic criteria" J Allergy Clin Immunol. (2010) 126(6):1099-104.

35

[128] Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ "Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations" J Allergy Clin Immunol. (2011) 128(1):147-152.

[129] Valent P "Mast cell activation syndromes: definition and classification" Allergy (2013) [Epub ahead of print 15 Feb. 2013].

40

### Claims

45

1. An H1 receptor antagonist and an H2 receptor antagonist for use in treating a patient having chronic idiopathic diarrhea, wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof.

50

2. An H1 receptor antagonist and an H2 receptor antagonist for use in treating a patient having IBS-diarrhea predominate (IBS-D), wherein the patient does not have mastocytic enterocolitis, wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof.

55

3. A pharmaceutical composition for use in treating a patient having chronic idiopathic diarrhea, said pharmaceutical composition comprising:

a. an H1 receptor antagonist, wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof; and

b. an H2 receptor antagonist.

60

4. A pharmaceutical composition for use in treating a patient having IBS-D, wherein the patient does not have mastocytic enterocolitis, said pharmaceutical composition comprising:

a. an H1 receptor antagonist, wherein the H1 receptor antagonist comprises cetirizine, levocetirizine, or mixtures thereof; and

b. an H2 receptor antagonist.

65

5. The H1 receptor antagonist and H2 receptor antagonist for use, or pharmaceutical composition for use according

to any one of the preceding claims, wherein the H2 receptor antagonist comprises famotidine, ranitidine, or mixtures thereof.

- 6. The H1 receptor antagonist and H2 receptor antagonist for use, or pharmaceutical composition for use according to any one of the preceding claims, wherein the H1 receptor antagonist and the H2 receptor antagonist are administered simultaneously.
- 7. The H1 receptor antagonist and H2 receptor antagonist for use, or pharmaceutical composition for use according to any one of the preceding claims, wherein the H1 receptor antagonist and the H2 receptor antagonist are administered once per day for at least 2 days or for at least 7 days.
- 8. The H1 receptor antagonist and H2 receptor antagonist for use, or pharmaceutical composition for use according to any one of the preceding claims, wherein cetirizine is administered in an amount of 5 to 20 mg and/or wherein famotidine is administered in an amount of 10 to 40 mg.
- 9. The H1 receptor antagonist and H2 receptor antagonist for use, or pharmaceutical composition for use according to any one of the preceding claims, wherein famotidine and cetirizine are administered together as a unit dosage form.
- 10. The pharmaceutical composition for use according to any one of claims 3-9, wherein the pharmaceutical composition is an oral dosage form.

### Patentansprüche

- 1. H1-Rezeptorantagonist und H2-Rezeptorantagonist zur Verwendung bei der Behandlung eines Patienten mit chronischer idiopathischer Diarröhö, wobei der H1-Rezeptorantagonist Cetirizin, Levocetirizin oder Gemische davon umfasst.
- 2. H1-Rezeptorantagonist und H2-Rezeptorantagonist zur Verwendung bei der Behandlung eines Patienten mit Diarröhöprädominantem Reizdarmsyndrom (RDS-D), wobei bei dem Patienten keine mastozytäre Enterokolitis vorliegt, wobei der H1-Rezeptorantagonist Cetirizin, Levocetirizin oder Gemische davon umfasst.
- 3. Pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung eines Patienten mit chronischer idiopathischer Diarröhö, wobei die genannte pharmazeutische Zusammensetzung Folgendes umfasst:
  - a. einen H1-Rezeptorantagonisten, wobei der H1-Rezeptorantagonist Cetirizin, Levocetirizin oder Gemische davon umfasst; und
  - b. einen H2-Rezeptorantagonisten.
- 4. Pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung eines Patienten mit RDS-D, wobei bei dem Patienten keine mastozytäre Enterokolitis vorliegt, wobei die genannte pharmazeutische Zusammensetzung Folgendes umfasst:
  - a. einen H1-Rezeptorantagonisten, wobei der H1-Rezeptorantagonist Cetirizin, Levocetirizin oder Gemische davon umfasst; und
  - b. einen H2-Rezeptorantagonisten.
- 5. H1-Rezeptorantagonist und H2-Rezeptorantagonist zur Verwendung oder pharmazeutische Zusammensetzung zur Verwendung nach einem der vorangehenden Ansprüche, wobei der H2-Rezeptorantagonist Famotidin, Ranitidin oder Gemische davon umfasst.
- 6. H1-Rezeptorantagonist und H2-Rezeptorantagonist zur Verwendung oder pharmazeutische Zusammensetzung zur Verwendung nach einem der vorangehenden Ansprüche, wobei der H1-Rezeptorantagonist und der H2-Rezeptorantagonist simultan verabreicht werden.
- 7. H1-Rezeptorantagonist und H2-Rezeptorantagonist zur Verwendung oder pharmazeutische Zusammensetzung zur Verwendung nach einem der vorangehenden Ansprüche, wobei der H1-Rezeptorantagonist und der H2-Rezeptorantagonist einmal täglich für mindestens zwei Tage oder für mindestens sieben Tage verabreicht werden.

8. H1-Rezeptorantagonist und H2-Rezeptorantagonist zur Verwendung oder pharmazeutische Zusammensetzung zur Verwendung nach einem der vorangehenden Ansprüche, wobei Cetirizin in einer Menge von 5 mg bis 20 mg verabreicht wird und/oder wobei Famotidin in einer Menge von 10 mg bis 40 mg verabreicht wird.
- 5 9. H1-Rezeptorantagonist und H2-Rezeptorantagonist zur Verwendung oder pharmazeutische Zusammensetzung zur Verwendung nach einem der vorangehenden Ansprüche, wobei Famotidin und Cetirizin zusammen als eine Einzeldarreichungsform verabreicht werden.
- 10 10. Pharmazeutische Zusammensetzung zur Verwendung nach einem der Ansprüche 3 bis 9, wobei die pharmazeutische Zusammensetzung eine orale Darreichungsform ist.

#### Revendications

- 15 1. Antagoniste du récepteur H1 et antagoniste du récepteur H2 destinés à une utilisation dans le traitement d'un patient présentant une diarrhée idiopathique chronique, l'antagoniste du récepteur H1 comprenant la cétirizine, la lévocétirizine, ou des mélanges de celles-ci.
- 20 2. Antagoniste du récepteur H1 et antagoniste du récepteur H2 destinés à une utilisation dans le traitement d'un patient présentant un SCI avec diarrhées (SCI-D), le patient ne présentant pas d'entérocolite à mastocytes, et l'antagoniste du récepteur H1 comprenant la cétirizine, la lévocétirizine, ou des mélanges de celles-ci.
- 25 3. Composition pharmaceutique destinée à une utilisation dans le traitement d'un patient présentant une diarrhée idiopathique chronique, ladite composition pharmaceutique comprenant :
  - a. un antagoniste du récepteur H1, l'antagoniste du récepteur H1 comprenant la cétirizine, la lévocétirizine, ou des mélanges de celles-ci ; et
  - b. un antagoniste du récepteur H2.
- 30 4. Composition pharmaceutique destinée à une utilisation dans le traitement d'un patient présentant un SCI-D, le patient ne présentant pas d'entérocolite à mastocytes, et ladite composition pharmaceutique comprenant :
  - a. un antagoniste du récepteur H1, l'antagoniste du récepteur H1 comprenant la cétirizine, la lévocétirizine, ou des mélanges de celles-ci ; et
  - b. un antagoniste du récepteur H2.
- 35 5. Antagoniste du récepteur H1 et antagoniste du récepteur H2 destinés à une utilisation, ou composition pharmaceutique destinée à une utilisation selon l'une quelconque des revendications précédentes, l'antagoniste du récepteur H2 comprenant la famotidine, la ranitidine, ou des mélanges de celles-ci.
- 40 6. Antagoniste du récepteur H1 et antagoniste du récepteur H2 destinés à une utilisation, ou composition pharmaceutique destinée à une utilisation selon l'une quelconque des revendications précédentes, l'antagoniste du récepteur H1 et l'antagoniste du récepteur H2 étant administrés simultanément.
- 45 7. Antagoniste du récepteur H1 et antagoniste du récepteur H2 destinés à une utilisation, ou composition pharmaceutique destinée à une utilisation selon l'une quelconque des revendications précédentes, l'antagoniste du récepteur H1 et l'antagoniste du récepteur H2 étant administrés une fois par jour pendant au moins 2 jours ou pendant au moins 7 jours.
- 50 8. Antagoniste du récepteur H1 et antagoniste du récepteur H2 destinés à une utilisation, ou composition pharmaceutique destinée à une utilisation selon l'une quelconque des revendications précédentes, la cétirizine étant administrée dans une quantité de 5 à 20 mg, et/ou la famotidine étant administrée dans une quantité de 10 à 40 mg.
- 55 9. Antagoniste du récepteur H1 et antagoniste du récepteur H2 destinés à une utilisation, ou composition pharmaceutique destinée à une utilisation selon l'une quelconque des revendications précédentes, la famotidine et la cétirizine étant administrées ensemble comme une forme galénique unitaire.
10. Composition pharmaceutique destinée à une utilisation selon l'une quelconque des revendications 3 à 9, la com-

position pharmaceutique étant une forme galénique orale.

5

10

15

20

25

30


35

40

45

50

55



**FIG. 1**

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 2008128115 A2 [0007]
- US 2009042972 A1 [0008]

## Non-patent literature cited in the description

- **RUNGE et al.** Histamine antagonists in the treatment of acute allergic reactions. *Ann Emerg Med*, March 1992, vol. 21, 237-242 [0005] [0059]
- **LIN et al.** Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. *Ann Emerg Med*, November 2000, vol. 36, 462-468 [0005] [0059]
- **GHADIR et al.** *Tehran University Medical Journal*, 2011, vol. 69 (6), 352-358 [0006]
- **SPIEGEL et al.** *Clin Neuropharmacol*, 2011, vol. 34 (1), 36-38 [0009]
- **JAKATE et al.** *Arch Pathol Lab Med*, 2006, vol. 130, 362-367 [0010]
- **FONDACARO et al.** *Journal of Pharmacological Methods*, 1990, vol. 24, 59-71 [0011]
- **BERRY et al.** *Gut*, 1974, vol. 15, 34-38 [0012]
- **JAKATE et al.** Mastocytic Enterocolitis: Increased mucosal mast cells in chronic intractable diarrhea. *Arch Pathol Lab Med*, 2006, vol. 130, 362-367 [0023] [0034]
- **SCHILLER LR.** Secretory Diarrhea. *Current Gastroenterology Reports*, 1999, vol. 1, 389-397 [0059]
- **SCHILLER, LR ; HOGAN RB ; MORAWSKI, SG ; SANTA ANA, CA ; BERN MJ ; NOGAARD, RP ; BO-LINN, GW ; FORDTRAN JS.** Studies of the Prevalence and Significance of Radiolabeled Rice Acid Malabsorption in a Group of Patients with Idiopathic Chronic Diarrhea. *Gastroenterology*, 1997, vol. 92, 151-160 [0059]
- **FORDTRAN JS ; SANTA ANA CA ; MORAWSKI SG et al.** Pathophysiology of chronic diarrhea: insights derived from intestinal perfusion studies in 31 patients. *Gastroenterol Clin North Am*, 1986, vol. 15, 477-490 [0059]
- **LUNARDI C ; BAMBARA LM ; BIASI D et al.** Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. *Clin Exp Allergy*, 1991, vol. 21, 569-572 [0059]
- **FINE KD ; SCHILLER UR.** AGA technical review on the evaluation and management of chronic diarrhea. *Gastroenterology*, 1999, vol. 116, 1464-1486 [0059]
- **O'SULLIVAN et al.** Increased mast cells in the irritable bowel syndrome. *Neurogastroenterol Mot.*, 2000, vol. 12, 449-457 [0059]
- **SPILLER RC ; JENKINS D ; THORNLEY JP ; HEBDEN JM ; WRIGHT T ; SKINNER M ; NEAL KR.** Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute *Campylobacter* enteritis and in post-dysenteric irritable bowel syndrome. *Gut*, December 2000, vol. 47 (6), 804-11 [0059]
- **THEOHARIDES TC ; COCHRANE DE.** Critical role of Mast Cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol*, 2004, vol. 146, 1-12 [0059]
- **BARBARS G ; DE GIORGIO et al.** New pathophysiological mechanisms in irritable bowel syndrome. *Aliment Pharmacol Ther*, 2004, vol. 20 (2), 1-9 [0059]
- **DUNLOP SP, HEBDEN et al.** Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. *Am J Gastroenterol*, 2006, vol. 101 (6), 1288-1294 [0059]
- **BARBARA G ; STANGHELLINI V et al.** Functional gastrointestinal disorders and mast cells: implications for therapy. *Neurogastroenterol Motil*, 2006, vol. 18, 6-17 [0059]
- **HALVORSON HA et al.** Postinfectious irritable bowel syndrome-a meta-analysis. *Am J Gastroenterol*, 2006, vol. 101, 1894-1899 [0059]
- **POSSEURUD I et al.** Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. *Gut*, 2007, vol. 56, 802-808 [0059]
- **LEWIS, J ; CANDELORA, J ; HOGAN, II, RB ; BRIGGS, F ; ABRAHAM, S.** Crystal-Storing Histiocytosis Due to Massive Accumulation of Charcot-Leyden Crystals: A Unique Association Producing Colonic Polyposis in a 78-year-old Woman With Eosinophilic Colitis. *Am J Surg Pathol.*, March 2007, vol. 321 (3), 481-485 [0059]
- **JAKATE S et al.** Mastocytic enterocolitis increased mucosal mast cells in chronic intractable diarrhea. *Arch Pathol Lab Med*, 2006, vol. 130, 362-367 [0059]
- **KIRSCH RH ; RIDDELL R.** Histopathological alterations in irritable bowel syndrome. *Modem Pathology*, 2006, vol. 19, 1638-1645 [0059]

- **RAMOS L ; VICARIO M ; SANTOS J.** Stress-mast cell axis and regulation of gut mucosal inflammation: from intestinal health to an irritable bowel. *Med Clin (Barc)*, June 2007, vol. 129 (2), 61-69 [0059]
- **PICHE T ; SAINT-PAUL MC et al.** Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. *Gut*, 2008, vol. 57, 468-473 [0059]
- **VISSER J, ROZING et al.** Tight Junctions, intestinal permeability and autoimmunity celiac disease and type 1 diabetes paradigms. *Ann N Y Acad Sci*, 2009, vol. 1165, 195-205 [0059]
- **WALKER MM ; TALLEY NJ et al.** Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. *Aliment Pharmacol Ther*, 2009, vol. 29, 765-773 [0059]
- **THABANE M ; MARSHALL JK.** Post-infectious irritable bowel syndrome. *World J Gastroenterol*, 2009, vol. 15 (29), 3591-3596 [0059]
- **WALKER MM ; SALEHIAN SS et al.** Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia. *Aliment Pharmacol Ther*, 2010, vol. 31, 1229-1236 [0059]
- **KLOOKER TK ; BRAAK B ; KOOPMAN KE et al.** The mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. *Gut*, 2010, vol. 59, 1213-21 [0059]
- **MARTINEZ C et al.** The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations. *Am J Gastroenterol*, 2012, vol. 107, 736-746 [0059]
- **THEOHARIDES TC ; SHAHZAD A ; CHEN J ; HUIZINGA J.** Irritable Bowel Syndrome and the Elusive Mast Cell. *Am J Gastroenterol*, 2012, vol. 107, 727-729 [0059]
- **SMITH MJ.** IBS remains a mysterious disorder with few effective Remedies. *Gastroenterology and Endoscopy News*, April 2012, vol. 63, 4 [0059]
- **PYLERIS E ; GIAMARELOS-BOURBOULIS EJ et al.** The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. *Dig Dis Sci.*, May 2012, vol. 57 (5), 1321-9 [0059]
- **VIVINUS-NEBOT M ; DAINESER et al.** Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. *ACG*, 2012, vol. 107, 74-81 [0059]
- **AKHAVEIN A ; PATEL NR et al.** Allergic Mastocytic Gastroenteritis and colitis: and unexplained etiology in chronic abdominal pain and gastrointestinal dysmotility. *Gastroenter Research and Practice*, 2012, 950582 [0059]
- **MARTINEZ C ; LOBO B et al.** Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. *Gut*, 2012 [0059]
- **BRAAK B ; KLOOKER TK et al.** Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?. *Am J Gastroenterol*, 2012, vol. 107, 715-726 [0059]
- **THEOHARIDES TC ; ASADI S ; CHEN J ; HUIZINGA J.** Irritable bowel syndrome and the elusive mast cells. *Am J Gastroenterol*, 2012, vol. 107 (5), 727-729 [0059]
- **FARHADIA ; FIELDS JZ ; KESHAVARZIAN A.** Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. *World J Gastroenterol*, 2007, vol. 13 (22), 3027-3030 [0059]
- **JUCKETT G ; TRIVEDI R.** Evaluation of chronic diarrhea. *American Family Physician*, 15 November 2011, vol. 84 (10), 1119-1126 [0059]
- Diarrhea [electronic resource]/ National Digestive Diseases Information Clearinghouse. U.S. Dept. of Health and Human Services, National Institutes of Diabetes and Digestive and Kidney Diseases, 2011 [0059]
- **FORBES D ; O'LOUGHLIN E ; SCOTT R ; GALL D.** Laxative abuse and secretory diarrhoea. *Arch Dis Child*, 1985, vol. 60 (1), 58-60 [0059]
- **DUPONT, H.L. et al.** Diarrhea. *National Digestive Diseases Information Clearinghouse*, January 2012 [0059]
- Acute Diarrhea. **LEVER, D.D. et al.** Center for Continuing Education publications: Disease Management Project. Cleveland Clinic, 01 August 2010 [0059]
- H2 blockers, MedlinePlus®. U.S. National Library of Medicine, NIH, 11 August 2011 [0059]
- **HE, SHUANG ; LI, FENG ; ZHOU, DAN ; DU, JUNRONG ; HUANG, YUAN.** *Drug development and industrial pharmacy*, October 2012, vol. 38 (10), 1280-1289 [0059]
- **AKIN C ; VALENT P ; METCALFE DD.** Mast cell activation syndrome: Proposed diagnostic criteria. *J Allergy Clin Immunol.*, 2010, vol. 126 (6), 1099-104 [0059]
- **HAMILTON MJ ; HORNICK JL ; AKIN C ; CASTELLS MC ; GREENBERGER NJ.** Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. *J Allergy Clin Immunol.*, 2011, vol. 128 (1), 147-152 [0059]
- **VALENT P.** Mast cell activation syndromes: definition and classification. *Allergy*, 2013 [0059]